Shenzhen Kangtai Biological Products Co Ltd
300601
Company Profile
Business description
Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
Contact
No. 6 Kefa Road
Science and Technology Industrial Park
Nanshan District
Shenzhen518057
CHNT: +86 75526988688
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,913
Stocks News & Analysis
stocks
After Earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,867.37 | 10.01 | 0.13% |
| DAX 40 | 24,185.75 | 31.62 | -0.13% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,094.42 | 41.90 | -0.46% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |